Recent Investment Analysts’ Ratings Changes for Ionis Pharmaceuticals (IONS)

A number of research firms have changed their ratings and price targets for Ionis Pharmaceuticals (NASDAQ: IONS):

• 10/22/2026 – Ionis Pharmaceuticals had its “buy” rating reaffirmed by HC Wainwright.
• 10/22/2026 – Ionis Pharmaceuticals was upgraded by BMO Capital Markets from “market perform” to “outperform”. They now have a $66.00 price target on the stock, up from $54.00.
• 10/21/2026 – Ionis Pharmaceuticals had its “buy” rating reaffirmed by Citigroup.
• 10/20/2026 – Ionis Pharmaceuticals was given a new $79.00 price target by Raymond James Financial.
• 10/15/2026 – Ionis Pharmaceuticals had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 10/15/2026 – Ionis Pharmaceuticals is now covered by UBS Group. They set a “buy” rating and a $88.00 price target on the stock.
• 9/24/2026 – Ionis Pharmaceuticals had its “outperform” rating reaffirmed by Oppenheimer. They now have a $85.00 price target on the stock.
• 9/24/2026 – Ionis Pharmaceuticals had its “buy” rating reaffirmed by HC Wainwright. They now have a $100.00 price target on the stock.
• 9/22/2026 – Ionis Pharmaceuticals had its price target lowered by JPMorgan Chase & Co. from $76.00 to $70.00. They now have an “overweight” rating on the stock.
• 9/15/2026 – Ionis Pharmaceuticals had its price target lowered by Guggenheim from $89.00 to $80.00. They now have a “buy” rating on the stock.
• 9/9/2026 – Ionis Pharmaceuticals had its price target lowered by Barclays from $90.00 to $85.00. They now have an “overweight” rating on the stock.
• 9/8/2026 – Ionis Pharmaceuticals had its “outperform” rating reaffirmed by Raymond James Financial. They now have a $84.00 price target on the stock.
• 9/8/2026 – Ionis Pharmaceuticals had its price target lowered by Morgan Stanley from $110.00 to $104.00. They now have an “overweight” rating on the stock.
• 9/8/2026 – Ionis Pharmaceuticals had its “buy” rating reaffirmed by TD Cowen.
• 9/8/2026 – Ionis Pharmaceuticals had its price target lowered by BMO Capital Markets from $61.00 to $54.00. They now have a “market perform” rating on the stock.
• 9/8/2026 – Ionis Pharmaceuticals had its price target lowered by The Goldman Sachs Group from $69.00 to $56.00. They now have a “neutral” rating on the stock.
• 9/8/2026 – Ionis Pharmaceuticals had its price target lowered by HC Wainwright from $115.00 to $100.00. They now have a “buy” rating on the stock.
• 9/8/2026 – Ionis Pharmaceuticals had its price target lowered by Canaccord Genuity Group from $95.00 to $85.00. They now have a “buy” rating on the stock.

Ionis Pharmaceuticals Price Performance

Shares of Ionis Pharmaceuticals stock traded down $0.27 during trading on Wednesday, hitting $40.15. The stock had a trading volume of 4,102,736 shares, compared to its average volume of 2,666,506. The company has a debt-to-equity ratio of 3.07, a current ratio of 7.89 and a quick ratio of 7.73. The firm has a market cap of $6.67 billion, a P/E ratio of -11.60 and a beta of 0.43. The business has a fifty day moving average of $48.22 and a two-hundred day moving average of $66.44. Ionis Pharmaceuticals, Inc. has a fifty-two week low of $39.33 and a fifty-two week high of $86.74.

Insider Transactions at Ionis Pharmaceuticals

In other Ionis Pharmaceuticals news, EVP Shannon Devers sold 1,357 shares of the business’s stock in a transaction dated Friday, October 16th. The shares were sold at an average price of $43.54, for a total value of $59,083.78. Following the sale, the executive vice president directly owned 17,811 shares in the company, valued at approximately $775,490.94. The trade was a 7.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 1.81% of the stock is currently owned by insiders.

Ionis Pharmaceuticals, Inc is a biotechnology company focused on discovering and developing medicines using antisense technology. Its platform is designed to selectively target RNA and regulate the production of disease-related proteins. The company develops therapies for neurological, cardiovascular and metabolic, and rare diseases.

Ionis has developed and commercialized medicines both independently and through collaborations with larger pharmaceutical companies. Its marketed or partnered products include Spinraza (nusinersen) for spinal muscular atrophy, Tegsedi (inotersen) and Wainua (eplontersen) for hereditary transthyretin amyloidosis, and Tryngolza (olezarsen) for familial chylomicronemia syndrome.